PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.
South Plainfield, US
Size (employees)
320 (est)
PTC Therapeutics was founded in 1998 and is headquartered in South Plainfield, US

PTC Therapeutics Office Locations

PTC Therapeutics has office in South Plainfield
South Plainfield, US

PTC Therapeutics Metrics

PTC Therapeutics Summary

Market capitalization

$288 m

Closing share price

PTC Therapeutics's current market capitalization is $288 m.

PTC Therapeutics Financials

We estimate that PTC Therapeutics's revenue is $82.7 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016


$34.7 m$25.2 m$36.8 m$82.7 m

Revenue growth, %


Net Income

($66.4 m)($93.8 m)($170.4 m)

PTC Therapeutics Market Value History

PTC Therapeutics Online Presence

PTC Therapeutics News

PTC Therapeutics Company Life

You may also be interested in